CD1D and neoplasm: For CD1d+ AML cells (e.g., THP1-FG and THP1-FGCD33-/-), the addition of αGC significantly enhanced antitumor efficacy of Allo15CAR33-NKT cells, while for CD1d- AML cells (e.g., HL60-FG and THP1-FGCD1d-/-), the addition of αGC did not boost tumor cell killing, suggesting that Allo15CAR33-NKT cells can target AML tumor cells via NKT TCR-mediated pathways (Fig. 3e and Supplementary Fig. 7a).